Press

Canadian Survey Shows People Aren’t Talking to Doctors About Medical Use of Psychedelics

Aug 25 • 3 min read

A recent Canadian survey has revealed that an increasing number of people are taking psychedelics for therapeutic purposes but aren’t discussing their psychedelic use with their doctors. The poll discovered that Canadians are specifically using hallucinogens to address mental health challenges but aren’t informing their physicians about the psychedelic use. Published in the “Journal of…

Sunstone Therapies in Collaboration with the University of Vermont Announces Publication of Study Showing Feasibility of Direct Observation of Therapeutic Connection in Psilocybin-Assisted Therapy

Aug 25 • 3 min read

Sunstone Therapies in Collaboration with the University of Vermont Announces Publication of Study Showing Feasibility of Direct Observation of Therapeutic Connection in Psilocybin-Assisted Therapy Study demonstrates potential to operationalize observation of therapeutic connection with implications for therapist training and clinical settings Sunstone Therapies, a leader in the delivery of psychedelic-assisted therapy in the medical setting…

Societal CDMO Announces Pricing of $8.3 Million Public Offering of Common Stock

Aug 24 • 3 min read

Societal CDMO, Inc. (“Societal”; NASDAQ: SCTL), a contract development and manufacturing organization (“CDMO”) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today announced the pricing of its previously announced underwritten public offering of 20,750,000 shares of its common stock (or common stock equivalents) at a public offering price of…

Incannex to Prepare FDA IND Application for Psilocybin-assisted Psychedelic Psychotherapy Program, Known as Psi-GAD

Aug 24 • 4 min read

Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), a clinical-stage pharmaceutical company developing unique medicinal cannabinoid pharmaceutical products and psychedelic medicine therapies for unmet medical needs, is pleased to announce that its subsidiary Psychennex Pty Ltd has commenced preparations of an investigational new drug (‘IND’) application to the U.S. Food and Drug Administration (‘FDA’) for the…

Core One Labs : Commends Study Exploring Psychedelics’ Efficacy in Providing Relief for Chronic Pain Conditions

Aug 24 • 3 min read

Core One Labs Inc. (CSE: COOL), (OTCQB: CLABF), (Frankfurt: LD6, WKN: A3CSSU) (the “Company” or “Core One“) applauds a recent survey study published in the European Journal of Pain, which suggests that psychedelic substances could offer potential therapeutic value in addressing specific chronic pain conditions. By conducting an extensive survey among 170 individuals dealing with chronic pain and who met…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441